Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health
NCT ID: NCT05170113
Last Updated: 2022-07-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
79 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-11-02
Study Completion Date
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the effectiveness and safety of the Alpinia galanga formulation, Theacrine formulation, and Caffeine formulation on fatigue, mental acuity, and cognitive health among overall healthy participants
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Energy Shots and Caffeine for Energy and Wakefulness Levels
NCT01755299
Focus: to Compare a Commercially Available Energy Drink, B Vitamins, Caffeine Alone, and Placebo for Effectiveness on Perceived Energy Level and Wakefulness
COMPLETED
NA
Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood
NCT06384586
Cognition
Mental Fatigue
Mood
COMPLETED
NA
Effects of Energy Drink on Repeated Sprint Performance and Cognitive Function in Athletes
NCT07104188
Exercise Performance Impairment
Cognitive Function Decline
Fatigue
COMPLETED
NA
Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes
NCT05032729
Sleep
Physical Performance
Cognitive Performance
+1 more
COMPLETED
NA
Effects of Caffeine and L-Theanine on Physical and Cognitive Performance in Trained Athletes
NCT07268573
Cognitive Performance
Physical Performance Enhancement
Caffeine and L-theanine Interaction
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a 4-arm pilot, double-blind, randomized, placebo-controlled, parallel design study. A total of 80 subjects (20 per treatment arm) will be enrolled in a randomly assigned sequence to receive either the Alpinia galanga formulation, Theacrine formulation, Caffeine formulation, or placebo in individuals and admit to experiencing occasional fatigue (tiredness) and would like more energy.
Participants will need to complete assessments and questionnaires.
The primary objective is the evaluation of the change in the response to the VAS-F (Visual Analogue Scale to Evaluate Fatigue Severity) relative to baseline. The secondary objective is the evaluation of the change in the responses to the BCAT-SF (Brief Cognitive Health Assessment Short Form), LSEQ (Leeds Sleep Evaluation Questionnaires), and SF-36 Health Survey (Short Form 36) compared to baseline.
Safety and tolerability will be evaluated through the receipt of documentation and responses from the telephone contacts/ emails per protocol.
Participants will need to complete assessments and questionnaires.
The primary objective is the evaluation of the change in the response to the VAS-F (Visual Analogue Scale to Evaluate Fatigue Severity) relative to baseline. The secondary objective is the evaluation of the change in the responses to the BCAT-SF (Brief Cognitive Health Assessment Short Form), LSEQ (Leeds Sleep Evaluation Questionnaires), and SF-36 Health Survey (Short Form 36) compared to baseline.
Safety and tolerability will be evaluated through the receipt of documentation and responses from the telephone contacts/ emails per protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Fatigue
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alpinia galanga formulation
Alpinia galanga formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
Group Type
ACTIVE_COMPARATOR
Alpinia galanga formulation
Intervention Type
DIETARY_SUPPLEMENT
Alpinia galanga formulation capsule- 1 capsule daily
Theacrine formulation
Theacrine formulation capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
Group Type
ACTIVE_COMPARATOR
Theacrine formulation
Intervention Type
DIETARY_SUPPLEMENT
Theacrine formulation capsule- 1 capsule daily
Caffeine formulation.
Caffeine formulation capsule: Take one (1) capsules once daily at noon with 8 oz.(240 ml) of water for a 14-day dosing period
Group Type
ACTIVE_COMPARATOR
Caffeine formulation
Intervention Type
DIETARY_SUPPLEMENT
Caffeine formulation capsule- I capsule daily
Placebo
Placebo capsule: Take one (1) capsule once daily at noon with 8 oz. (240 ml) of water for a 14-day dosing period
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Placebo capsule- 1 capsule daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alpinia galanga formulation
Alpinia galanga formulation capsule- 1 capsule daily
Intervention Type
DIETARY_SUPPLEMENT
Theacrine formulation
Theacrine formulation capsule- 1 capsule daily
Intervention Type
DIETARY_SUPPLEMENT
Caffeine formulation
Caffeine formulation capsule- I capsule daily
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Placebo capsule- 1 capsule daily
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ambulatory, male or female, 30-70 years of age
2. A body mass index (BMI) of 18.5 - 34.9
3. Admits to experiencing occasional fatigue (tiredness) and would like more energy
4. Has consumed no more than two cups of coffee or caffeinated beverage per day for seven or more days before Screening/baseline
5. Has personal access to and able to operate a smartphone, tablet, or computer with enough memory to accommodate additional application(s) and reliable internet service
6. Able to complete tests online with a computer
7. Able to print out and return documents by scan, email, or mail
8. Has regular daytime work hours or shifts, if employed (regular shift excludes night shift workers and those with rotating shifts)
9. Generally healthy and having no significant difficulty with digestion or absorption of food
10. Able to complete an Activity Log and Study Product Log daily
11. Has been generally weight stable for the past six months (give or take 6 lbs.)
12. Willing and able to give written informed consent
13. Clearly understands the procedures and study requirements
14. Willing and able to comply with all study procedures, as per protocol
15. Able to communicate, including reading, in English
16. Has not taken any nutritional supplements that may contain any of the components of the study products including Alpinia galanga, Theacrine or Caffeine for a minimum of 14 days before Screening/baseline
2. A body mass index (BMI) of 18.5 - 34.9
3. Admits to experiencing occasional fatigue (tiredness) and would like more energy
4. Has consumed no more than two cups of coffee or caffeinated beverage per day for seven or more days before Screening/baseline
5. Has personal access to and able to operate a smartphone, tablet, or computer with enough memory to accommodate additional application(s) and reliable internet service
6. Able to complete tests online with a computer
7. Able to print out and return documents by scan, email, or mail
8. Has regular daytime work hours or shifts, if employed (regular shift excludes night shift workers and those with rotating shifts)
9. Generally healthy and having no significant difficulty with digestion or absorption of food
10. Able to complete an Activity Log and Study Product Log daily
11. Has been generally weight stable for the past six months (give or take 6 lbs.)
12. Willing and able to give written informed consent
13. Clearly understands the procedures and study requirements
14. Willing and able to comply with all study procedures, as per protocol
15. Able to communicate, including reading, in English
16. Has not taken any nutritional supplements that may contain any of the components of the study products including Alpinia galanga, Theacrine or Caffeine for a minimum of 14 days before Screening/baseline
Exclusion Criteria
1. Not having the basic skills needed to operate a smartphone, tablet, or computer
2. Unwilling to abstain from consuming more than two cups of coffee or caffeinated beverage/food per day and no caffeinated beverage/food after 10 am daily for the duration of the study
3. Having smoked any cigarette, electronic cigarette, cigar, or pipe, or used marijuana, any recreational drug or cannabidiol (CBD) in the past 30 days
4. Donated blood within the 30 days prior to Screening/baseline
5. Having participated in another study within 30 days before Screening/baseline
6. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
7. History of allergy or sensitivity to any component of the study products
8. Currently taking or having taken within the 30 days prior to Screening/baseline any medication(s) or supplement(s) which may have a stimulant effect in the judgment of the Study Investigator/Sub-investigator
9. Having been diagnosed, received medical treatment, or taking medication daily for any of the following medical condition(s):
* Chronic fatigue syndrome
* Fibromyalgia
* Sleep disorder, including sleep apnea
10. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Eating disorder
* Acute or chronic inflammatory disease or autoimmune disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem
* Having a history of an abnormal electrocardiogram (ECG) unless permitted to proceed in the judgment of the Study Investigator/Sub-Investigator(s)
* Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
* Hypertension (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Study Investigator/Sub-Investigator
11. Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic \[inherited\] disorder), including antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants, benzodiazepines, CNS depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs), pentazocine, phenothiazines, and tramadol. These may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
12. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including DHEA, estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study). This may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
13. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-Investigator, would preclude participation in the study
14. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
15. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos for the study period
16. History of known or suspected substance abuse (e.g., alcohol, opiates, Benzodiazepines, or amphetamines)
17. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-Investigator including use of other nutritional supplements, which will be evaluated on a case-by-case basis
2. Unwilling to abstain from consuming more than two cups of coffee or caffeinated beverage/food per day and no caffeinated beverage/food after 10 am daily for the duration of the study
3. Having smoked any cigarette, electronic cigarette, cigar, or pipe, or used marijuana, any recreational drug or cannabidiol (CBD) in the past 30 days
4. Donated blood within the 30 days prior to Screening/baseline
5. Having participated in another study within 30 days before Screening/baseline
6. Being pregnant or planning on becoming pregnant during study participation; or breast feeding
7. History of allergy or sensitivity to any component of the study products
8. Currently taking or having taken within the 30 days prior to Screening/baseline any medication(s) or supplement(s) which may have a stimulant effect in the judgment of the Study Investigator/Sub-investigator
9. Having been diagnosed, received medical treatment, or taking medication daily for any of the following medical condition(s):
* Chronic fatigue syndrome
* Fibromyalgia
* Sleep disorder, including sleep apnea
10. Presence of active or recurring clinically significant conditions as follows:
* Diabetes mellitus or other endocrine disease
* Eating disorder
* Acute or chronic inflammatory disease or autoimmune disease
* Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem
* Having a history of an abnormal electrocardiogram (ECG) unless permitted to proceed in the judgment of the Study Investigator/Sub-Investigator(s)
* Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction
* Thyroid disease (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
* Hypertension (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
* Neurologic condition/disease
* Cancer (unless skin cancer other than melanoma which has been treated \> 3 years before Screening/baseline)
* Liver, pancreatic, and kidney disease
* Pulmonary disease
* Blood coagulation disorder or other hematologic disease
* Other condition or medication use that would preclude participation in the study in the judgment of the Study Investigator/Sub-Investigator
11. Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic \[inherited\] disorder), including antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants, benzodiazepines, CNS depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs), pentazocine, phenothiazines, and tramadol. These may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
12. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including DHEA, estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for \> 3 months, with no anticipated change for the duration of the study). This may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
13. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-Investigator, would preclude participation in the study
14. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
15. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos for the study period
16. History of known or suspected substance abuse (e.g., alcohol, opiates, Benzodiazepines, or amphetamines)
17. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-Investigator including use of other nutritional supplements, which will be evaluated on a case-by-case basis
Minimum Eligible Age
30 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Supplement Formulators, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Swick, PhD
Role: PRINCIPAL_INVESTIGATOR
Life Extension
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Life Extension Clinical Research
Fort Lauderdale, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Alajmi MF, Mothana RA, Al-Rehaily AJ, Khaled JM. Antimycobacterial Activity and Safety Profile Assessment of Alpinia galanga and Tinospora cordifolia. Evid Based Complement Alternat Med. 2018 Jul 8;2018:2934583. doi: 10.1155/2018/2934583. eCollection 2018.
Reference Type
BACKGROUND
Alpinia. (2019, October 7). Natural medicines (database on the Internet). Somerville, MA: Therapeutic Research Center. Retrieved from https://naturalmedicines.therapeuticresearch.com/databases/food,-herbssupplements/professional.aspx?productid=276
Reference Type
BACKGROUND
Bello ML, Walker AJ, McFadden BA, Sanders DJ, Arent SM. The effects of TeaCrine(R) and caffeine on endurance and cognitive performance during a simulated match in high-level soccer players. J Int Soc Sports Nutr. 2019 Apr 18;16(1):20. doi: 10.1186/s12970-019-0287-6.
Reference Type
BACKGROUND
Brice CF, Smith AP. Effects of caffeine on mood and performance: a study of realistic consumption. Psychopharmacology (Berl). 2002 Nov;164(2):188-92. doi: 10.1007/s00213-002-1175-2. Epub 2002 Sep 4.
Reference Type
BACKGROUND
Caffeine. (2020, January 6). Natural Medicines (database on the Internet). Somerville, MA: Therapeutic Research Center. Retrieved from https://naturalmedicines.therapeuticresearch.com/references.aspx?productid=979
Reference Type
BACKGROUND
Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. J Nutr Health Aging. 2014 Apr;18(4):383-92. doi: 10.1007/s12603-014-0021-7.
Reference Type
BACKGROUND
Chudiwal, A., Jain, D., & Somani, R. (2010). Alpinia galanga Willd.-An overview on phytopharmacological properties. Indian Journal of Natural Products and Resources, 1(2), 143-149.
Reference Type
BACKGROUND
Clewell A, Hirka G, Glavits R, Palmer PA, Endres JR, Murbach TS, Marx T, Pasics Szakonyine I. A 90-Day Oral Toxicological Evaluation of the Methylurate Purine Alkaloid Theacrine. J Toxicol. 2016;2016:6206859. doi: 10.1155/2016/6206859. Epub 2016 Aug 22.
Reference Type
BACKGROUND
Dallal, G. (2017, July 10). www.Randomization.com. Retrieved from Randomization.com: http://www.randomization.com
Reference Type
BACKGROUND
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999 Mar;51(1):83-133. No abstract available.
Reference Type
BACKGROUND
Ghosh S, Rangan L. Alpinia: the gold mine of future therapeutics. 3 Biotech. 2013 Jun;3(3):173-185. doi: 10.1007/s13205-012-0089-x. Epub 2012 Sep 18.
Reference Type
BACKGROUND
Haller CA, Jacob P 3rd, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther. 2002 Jun;71(6):421-32. doi: 10.1067/mcp.2002.124523.
Reference Type
BACKGROUND
Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl). 2005 Jun;179(4):813-25. doi: 10.1007/s00213-004-2104-3. Epub 2005 Jan 28.
Reference Type
BACKGROUND
Taylor L, Mumford P, Roberts M, Hayward S, Mullins J, Urbina S, Wilborn C. Safety of TeaCrine(R), a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use. J Int Soc Sports Nutr. 2016 Jan 13;13:2. doi: 10.1186/s12970-016-0113-3. eCollection 2016.
Reference Type
BACKGROUND
He H, Ma D, Crone LB, Butawan M, Meibohm B, Bloomer RJ, Yates CR. Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. J Caffeine Res. 2017 Sep 1;7(3):95-102. doi: 10.1089/jcr.2017.0006.
Reference Type
BACKGROUND
Kamimori GH, McLellan TM, Tate CM, Voss DM, Niro P, Lieberman HR. Caffeine improves reaction time, vigilance and logical reasoning during extended periods with restricted opportunities for sleep. Psychopharmacology (Berl). 2015 Jun;232(12):2031-42. doi: 10.1007/s00213-014-3834-5. Epub 2014 Dec 21.
Reference Type
BACKGROUND
Kuhman DJ, Joyner KJ, Bloomer RJ. Cognitive Performance and Mood Following Ingestion of a Theacrine-Containing Dietary Supplement, Caffeine, or Placebo by Young Men and Women. Nutrients. 2015 Nov 19;7(11):9618-32. doi: 10.3390/nu7115484.
Reference Type
BACKGROUND
McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016 Dec;71:294-312. doi: 10.1016/j.neubiorev.2016.09.001. Epub 2016 Sep 6.
Reference Type
BACKGROUND
Institute of Medicine (US) Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academies Press (US); 2001. Available from http://www.ncbi.nlm.nih.gov/books/NBK223802/
Reference Type
BACKGROUND
Meredith SE, Juliano LM, Hughes JR, Griffiths RR. Caffeine Use Disorder: A Comprehensive Review and Research Agenda. J Caffeine Res. 2013 Sep;3(3):114-130. doi: 10.1089/jcr.2013.0016.
Reference Type
BACKGROUND
Nehlig A. Is caffeine a cognitive enhancer? J Alzheimers Dis. 2010;20 Suppl 1:S85-94. doi: 10.3233/JAD-2010-091315.
Reference Type
BACKGROUND
Office of New Drugs. (2005). Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 1-37. Office of the Federal Register , National Archives and Record Administration.
Reference Type
BACKGROUND
Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med. 1992 Apr;58(2):124-7. doi: 10.1055/s-2006-961412.
Reference Type
BACKGROUND
Rosner, B. (n.d.). Hypothesis Testing: Two-Sample Inference-Estimation of Sample Size and Power for Comparing Two Means. In B. Rosner, Fundamentals of Biostatistics. Cengage Learning. Retrieved from www.stat.buc.ca: https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html
Reference Type
BACKGROUND
Saha S, Banerjee S. Central nervous system stimulant actions of Alpinia galanga (L.) rhizome: a preliminary study. Indian J Exp Biol. 2013 Oct;51(10):828-32.
Reference Type
BACKGROUND
Sebastiao AM, Ribeiro JA. Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol. 2009 Sep;7(3):180-94. doi: 10.2174/157015909789152128.
Reference Type
BACKGROUND
Hanish Singh JC, Alagarsamy V, Diwan PV, Sathesh Kumar S, Nisha JC, Narsimha Reddy Y. Neuroprotective effect of Alpinia galanga (L.) fractions on Abeta(25-35) induced amnesia in mice. J Ethnopharmacol. 2011 Oct 31;138(1):85-91. doi: 10.1016/j.jep.2011.08.048. Epub 2011 Sep 1.
Reference Type
BACKGROUND
Sivanandan, S., & Pimple, S. (2018). Molecular Docking Studies of Alpinia galanga Phytoconstituents for Psychostimulant Activity. Advances in Biological Chemistry, 8(4),69-80
Reference Type
BACKGROUND
Srivastava S, Mennemeier M, Pimple S. Effect of Alpinia galanga on Mental Alertness and Sustained Attention With or Without Caffeine: A Randomized Placebo-Controlled Study. J Am Coll Nutr. 2017 Nov-Dec;36(8):631-639. doi: 10.1080/07315724.2017.1342576. Epub 2017 Sep 14.
Reference Type
BACKGROUND
Srivastava, S., & Pimple, S. (2017). Effects of Cymbopogon Flexuosus, Alpinia Galanga, and Glycyrrhiza Glabra on attention: A randomized double-blind, placebo-controlled pilot study. BAOJ Nutrition, 3, 042.
Reference Type
BACKGROUND
van Gelder BM, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007 Feb;61(2):226-32. doi: 10.1038/sj.ejcn.1602495. Epub 2006 Aug 16.
Reference Type
BACKGROUND
Wang Y, Yang X, Zheng X, Li J, Ye C, Song X. Theacrine, a purine alkaloid with anti-inflammatory and analgesic activities. Fitoterapia. 2010 Sep;81(6):627-31. doi: 10.1016/j.fitote.2010.03.008. Epub 2010 Mar 20.
Reference Type
BACKGROUND
Warburton DM. Effects of caffeine on cognition and mood without caffeine abstinence. Psychopharmacology (Berl). 1995 May;119(1):66-70. doi: 10.1007/BF02246055.
Reference Type
BACKGROUND
Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J. 2011 Sep 13;10:93. doi: 10.1186/1475-2891-10-93.
Reference Type
BACKGROUND
Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr. 2004 Oct;80(4):862-7. doi: 10.1093/ajcn/80.4.862.
Reference Type
BACKGROUND
Ziegenfuss TN, Habowski SM, Sandrock JE, Kedia AW, Kerksick CM, Lopez HL. A Two-Part Approach to Examine the Effects of Theacrine (TeaCrine(R)) Supplementation on Oxygen Consumption, Hemodynamic Responses, and Subjective Measures of Cognitive and Psychometric Parameters. J Diet Suppl. 2017 Jan 2;14(1):9-24. doi: 10.1080/19390211.2016.1178678. Epub 2016 May 10.
Reference Type
BACKGROUND
Zwyghuizen-Doorenbos A, Roehrs TA, Lipschutz L, Timms V, Roth T. Effects of caffeine on alertness. Psychopharmacology (Berl). 1990;100(1):36-9. doi: 10.1007/BF02245786.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Xanthohumol on Resting Energy Expenditure and Substrate Oxidation in Healthy Women
NCT05711212
COMPLETED
NA
Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study
NCT04234529
COMPLETED
NA
A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults
NCT03731286
COMPLETED
NA
The Effect of a Caffeine Blend on Reaction Time, Mental Performance and Focus in Athletic Males
NCT03019523
COMPLETED
NA
Caffeine Kinetics and CrossFit®-Specific Performance
NCT05516212
RECRUITING
PHASE2/PHASE3
Botanical Supplement Muscle Function and Lean Body Mass
NCT03034668
COMPLETED
NA
The Effects Assessment of the Polygonatum Kingianum Extract on Endurance Performance and Anti-fatigue
NCT05877677
COMPLETED
NA
The Effects of 4 Week β-alanine Supplementation on Knee Extensor Contractile and Force Properties in the Over 60s
NCT03111979
SUSPENDED
PHASE4
A Study to Evaluate the Effect of EnXtra® and EnXtra® + Caffeine on Mental Alertness and Fatigue in Healthy Individuals
NCT06560008
COMPLETED
NA
The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation.
NCT07210099
RECRUITING
NA
Impact of Astaxanthin on Cognition in Recreationally Active Females
NCT06460181
RECRUITING
PHASE4
Caffeine and Resistance Training in Young Adults
NCT06610136
COMPLETED
NA
The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Trained Athletes.
NCT05926050
COMPLETED
NA
Effect of PeakATP on Mood, Reaction Time and Cognition
NCT05100589
COMPLETED
NA
Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance
NCT04712578
COMPLETED
NA
Effects of Supplementation With Ginseng and BCAA Improved Central Fatigue and Enhanced Attention During Exercise
NCT05129917
COMPLETED
NA
Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study
NCT04645394
COMPLETED
NA
Effectiveness of a Natural Ingredient on Obesity
NCT04105192
COMPLETED
NA
Dietary Supplementation on Fat Oxidation
NCT06548048
RECRUITING
NA
Safety Analysis of Chronic Intake of a β-alanine Supplement
NCT05334121
COMPLETED
NA
Investigating a Natural Antioxidant Food Product on Oxidative Stress in Recreationally Active Participants
NCT04959006
COMPLETED
NA
Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds
NCT02871596
COMPLETED
NA
The Effect of α-GPC on Cognitive Function and Sports Performance
NCT07267845
RECRUITING
NA
Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People
NCT02182934
COMPLETED
PHASE2
Effect of Acute Caffeine and Beetroot Juice Intake on Strength, Power, and Muscular Endurance
NCT06596395
COMPLETED
NA